Miousse Isabelle R
Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Science, Little Rock, Arkansas, United States.
Am J Physiol Cell Physiol. 2025 Jun 1;328(6):C1822-C1828. doi: 10.1152/ajpcell.00245.2025. Epub 2025 Apr 26.
A rapidly increasing proportion of the population in the United States is taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes or weight loss. Consequently, an increasing number of patients presenting with new cases of cancer also have a current prescription for GLP-1RAs. The impact of GLP-1RAs on metabolism is quite profound, and it is entirely reasonable to assume these agents are also very impactful on the metabolism of cancer cells, in addition to the general metabolism of the patient. Although these drugs are relatively recent on the market, the study of metabolism in cancer is a well-established field and we can make predictions about how GLP-1RAs will interface with cancer treatments. In fact, some evidence points to a possible neoadjuvant effect of these drugs for patients with cancer that would justify the initiation of GLP-1RAs to support therapy in a subset of patients. At the same time, there is a very present concern that drugs that induce weight loss may also precipitate the loss of muscle mass, cachexia, in patients. Here, we will provide an overview of the existing literature around diabetes and metabolism in the context of cancer and cachexia.
在美国，越来越多的人口正在服用胰高血糖素样肽-1受体激动剂（GLP-1RAs）来治疗2型糖尿病或用于减肥。因此，越来越多被诊断为癌症新病例的患者目前也正在使用GLP-1RAs。GLP-1RAs对新陈代谢的影响相当深远，除了对患者的整体新陈代谢有影响外，这些药物对癌细胞的新陈代谢也有很大影响，这是完全合理的假设。尽管这些药物在市场上相对较新，但癌症新陈代谢的研究是一个成熟的领域，我们可以预测GLP-1RAs将如何与癌症治疗相互作用。事实上，一些证据表明这些药物对癌症患者可能具有新辅助作用，这将证明在一部分患者中开始使用GLP-1RAs以支持治疗是合理的。与此同时，人们非常担心诱导体重减轻的药物也可能导致患者出现肌肉量减少即恶病质。在这里，我们将概述有关癌症和恶病质背景下糖尿病与新陈代谢的现有文献。
